GlyTherix Ltd is an Australian clinical-stage radiotheranostics company developing Miltuximab®, the world's first anti-GPC-1 antibody platform for solid tumours. GPC-1 is overexpressed across prostate, bladder, colorectal, pancreatic and other aggressive cancers — and is absent in healthy adult tissue, creating a uniquely clean therapeutic window.

The platform delivers two functions from a single antibody: 89Zr PET imaging for precise tumour detection, and 177Lu targeted radiotherapy. With $20M+ invested, a completed first-in-human safety study (zero drug-related adverse events across 12 patients), and an active imaging IIT underway, GlyTherix is the only company globally in clinical development on GPC-1.

Why work with us

The radioligand therapy field is consolidating fast. Eight acquisitions by Eli Lilly, Bristol Myers Squibb, AstraZeneca and Novartis in the past two years — averaging $1.8 billion each — have confirmed what oncology leaders already knew: targeted radiotherapy is the next major wave in cancer treatment.

Every one of those deals was built around PSMA or somatostatin receptors. The field is crowded there. GPC-1 is not.

GlyTherix holds a clear first-mover position on GPC-1 — a target with compelling biology, broad solid tumour expression, and zero approved therapies. Our Miltuximab® platform covers the full theranostic loop: image the patient, confirm targeting, then treat with precision. The same antibody. The same target. One elegant system.

We have done the hard work. The science is published. The first-in-human safety data is in. The imaging study is running now, and the data pharma licensing teams have told us they need is twelve months away.

We are not asking you to take a leap of faith on an untested idea. We are asking you to look seriously at the only clinical-stage GPC-1 asset in the world — at the moment it becomes actionable.

That window does not stay open indefinitely.